


REMARKS

This is in response to the Restriction Requirement mailed June 3, 2009. Applicants hereby elect Group I: claims 1-10, 28, and 29, drawn to a chemical compound, a pharmaceutical composition, and multiple process for preparing a chemical compound of formula (I).

Applicants further elect as a species the compound below, which is found, e.g., on page 77 of the specification and in claim 4:



N-[6-(2-{3-[4-Chloro-2-(2-methylamino-ethoxy)-5-trifluoromethyl-phenyl]-ureido}-ethyl)-1H-benzoimidazol-2-yl]-acetamide

Each of the claims of elected Group I read on the elected species.

Applicants request rejoinder of the non-elected subject matter of the method claims of Groups II-IV, and will perfect this request when compound claims are

considered allowable. Applicants also reserve the right to file one or more divisional applications directed to non-elected subject matter.

Applicants respectfully request examination of the instant application on the merits.

CONCLUSION

Should the Examiner believe that anything further is necessary in order to place this application in better condition for allowance, the Examiner is requested to contact the undersigned at the telephone number listed below.


In the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefore are hereby authorized to be charged to our Deposit Account No. 01-2300 referencing docket number 030863-00015.

Date: 7/1/09

Customer No. 04372
ARENT FOX LLP
1050 Connecticut Avenue, N.W.
Suite 400
Washington, D.C. 20036-5339
Telephone: (202) 857-6000
Facsimile: (202) 857-6395

RJK/ars

Respectfully submitted,

By: 
Ronald J. Kamis
Attorney for Applicants
Registration No. 41,104